RadNet (RDNT) Sets New 1-Year High at $13.25
RadNet Inc. (NASDAQ:RDNT) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $13.25 and last traded at $13.22, with a volume of 326479 shares. The stock had previously closed at $12.65.
Several research analysts have commented on the company. BidaskClub upgraded RadNet from a “hold” rating to a “buy” rating in a report on Wednesday. Raymond James Financial assumed coverage on RadNet in a report on Wednesday. They set a “strong-buy” rating and a $15.00 price objective on the stock. FIX assumed coverage on RadNet in a report on Wednesday. They set a “strong-buy” rating and a $15.00 price objective on the stock. Zacks Investment Research upgraded RadNet from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Jefferies Group set a $14.00 price objective on RadNet and gave the stock a “buy” rating in a report on Thursday, March 8th. One analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $13.75.
The company has a debt-to-equity ratio of 7.88, a quick ratio of 1.29 and a current ratio of 1.29. The company has a market cap of $590.54, a PE ratio of -1,325,000.00, a PEG ratio of 2.67 and a beta of 0.69.
In other news, insider John V. Crues sold 19,684 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $10.01, for a total value of $197,036.84. Following the completion of the sale, the insider now owns 544,097 shares of the company’s stock, valued at approximately $5,446,410.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Norman R. Hames sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $9.96, for a total value of $49,800.00. Following the completion of the sale, the executive vice president now directly owns 365,087 shares of the company’s stock, valued at approximately $3,636,266.52. The disclosure for this sale can be found here. 9.36% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of RDNT. JPMorgan Chase & Co. raised its position in RadNet by 85.7% in the third quarter. JPMorgan Chase & Co. now owns 503,880 shares of the medical research company’s stock valued at $5,795,000 after purchasing an additional 232,524 shares during the period. Renaissance Technologies LLC grew its stake in shares of RadNet by 18.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,404,444 shares of the medical research company’s stock worth $14,185,000 after acquiring an additional 223,740 shares during the period. EAM Investors LLC bought a new position in shares of RadNet during the 3rd quarter worth $2,364,000. Royce & Associates LP grew its stake in shares of RadNet by 683.9% during the 4th quarter. Royce & Associates LP now owns 176,368 shares of the medical research company’s stock worth $1,781,000 after acquiring an additional 153,868 shares during the period. Finally, Beck Mack & Oliver LLC grew its stake in shares of RadNet by 60.9% during the 4th quarter. Beck Mack & Oliver LLC now owns 352,916 shares of the medical research company’s stock worth $3,564,000 after acquiring an additional 133,515 shares during the period. 56.53% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/03/14/radnet-rdnt-sets-new-1-year-high-at-13-25.html.
RadNet Company Profile
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.